We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Targeted Nanogels Specifically Transport siRNA into Ovarian Cancer Cells

By LabMedica International staff writers
Posted on 01 Mar 2010
Nanoparticles crafted from hydrogels (nanogels) have been coated with receptor-specific peptides and used to transport siRNA (small, interfering RNA) capable of inhibiting the synthesis of epidermal growth factor receptor (EGFR) into ovarian cancer cells.

Targeted cancer therapy by RNA interference is a relatively new approach that can be used to silence reversibly genes in vivo. More...
In this study, RNA interference technology was used to shut down the gene for EGFR in ovarian cancer cells. Removal of this gene had been shown previously to increase the sensitivity of cancer cells to chemotherapeutic agents.

Delivery of the nucleic acid fragment has been the main hurdle delaying the broad development of siRNA-based therapeutics. In the current study, investigators at the Georgia Institute of Technology (Atlanta, USA) have gotten around this problem by protecting siRNA particles by enclosing them within hydrogel nanoparticles (nanogels). The siRNA was specific for the gene that encodes EGFR, which is highly overexpressed in some types of ovarian cancer. To ensure that the nanogels targeted only cancer cells, they were coated with peptides specific for the EphA2 receptor. Once bound to EphA2 receptors within the cancer cells the particles slowly released the siRNA over a timescale of days, allowing it to have a therapeutic effect.

Results published in the January 11, 2010, online edition of the journal BMC Cancer revealed that treatment of EphA2 positive Hey cells with siRNA-loaded, peptide-targeted nanogels decreased EGFR expression levels and significantly increased the sensitivity of this cell line to docetaxel. Nanogel treatment of SK-OV-3 cells, which are negative for EphA2 expression, failed to reduce EGFR levels and did not increase docetaxel sensitivity.

"With our technique we are inhibiting EGFR's growth, with small interfering RNA. And by inhibiting its growth, we are increasing the cell's apoptotic function. If we hit the cell with chemotherapy at the same time, we should be able to kill the cancer cells more effectively,” said senior author Dr. John McDonald, professor of biology at the Georgia Institute of Technology. "The fact that this system is releasing the siRNA slowly, without giving the cell time to immediately recover, gives us much better efficiency at killing the cancer cells with chemotherapy.”

Related Links:
Georgia Institute of Technology




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.